Scientific presentations
Patients with diabetes show poor adherence to heart disease drugs
March 1, 2020
Adherence to heart disease therapies dropped by half within one year
This study on diabetes looked at members newly diagnosed with diabetes who also had pre-existing cardiovascular disease (ASCVD). Three separate antihyperglycemic drug classes are recommended as add-on therapy for people with diabetes who also have ASCVD.
- Glucagon like peptide-1 agonists (GLP-1)
- Sodium-glucose cotransporter-2 inhibitors (SGLT-2i
- Dipeptidyl peptidase-4 inhibitors (DPP-4i)
All these medications require long-term adherence to reduce complications from ASCVD. But for all the drug classes in the study, adherence dropped off by about half within a year. (Yet the drug manufacturers reported adherence of 90% in their clinical trials.)
Related research
Scientific presentations
August 1, 2021
Prime’s analytics uncovers the hidden ups and downs behind the flat drug trend for MS DMDs
Insights from integrated medical and pharmacy claims show a big upswing in one…
Scientific presentations
June 21, 2021
Break autoimmune (AI) into indication-specific info for actionable strategy
Prime uses integrated medical and pharmacy data and breaks down largest drug category…
Scientific presentations
April 21, 2021
Prime links changes in adherence rates with total cost of care
Prime’s unique study of Medicare Advantage members uses integrated benefits data to show…